Creative Medical Technology Holdings, Inc. announced that it has received confirmation that Greenstone Biosciences Inc. in Palo Alto, CA has successfully developed a human induced pluripotent stem cell (iPSC) pipeline for the Company's ImmCelz(R) platform. In June 2022, the Company announced its collaboration with Greenstone Biosciences, Inc. on this project, called the iPScelz(TM) program, to enable the Company to increase its scalability for the ImmCelz(R") Immunotherapy Platform at a lower cost and continue its drug discovery program using artificial intelligence.
Creative Medical Technology Holdings, Inc.
Equities
CELZ
US22529Y4089
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.32 USD | -1.82% | -10.19% | -6.29% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.29% | 5.86M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CELZ Stock
- News Creative Medical Technology Holdings, Inc.
- Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform